| Cat.No. | Name | Information |
|---|---|---|
| M1806 | PD 0332991 HCL | PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. |
| M1974 | Roscovitine (Seliciclib) | Roscovitine is a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. |
| M2112 | LY2835219 mesylate | LY2835219 mesylate is an orally available inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively. |
| M1807 | SCH727965 (dinaciclib) | SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively. |
| M3519 | PHA-848125 | PHA-848125 is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. |
| M5228 | THZ1 | THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. |
| M1710 | Flavopiridol | Flavopiridol (Alvocidib) is a competitive broad-spectrum CDK inhibitor with IC50 of 30,170,100 nM against CDK1, CDK2 and CDK4, respectively. |
| M6167 | Palbociclib | Palbociclib is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases. |
| M5305 | RO-3306 | RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases. |
| M4889 | Ribociclib succinate (LEE011 succinate) | Ribociclib succinate (LEE011 succinate) is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
| M41437 | Tibremciclib | Tibremciclib is a CDK4 inhibitor with antineoplastic activity. |
| M41436 | CDK2/Bcl2-IN-1 | CDK2/Bcl2-IN-1 with promising cytotoxicity against cancer cells. |
| M41435 | CDK9-IN-23 | CDK9-IN-23 is a CDK9 inhibitor with an IC50 of <20 nM. |
| M41434 | PROTAC CDK9 degrader-7 | PROTAC CDK9 degrader-7 is a PROTAC targeting to CDK9 sepcifically. |
| M41433 | PROTAC CDK9 degrader-6 | PROTAC CDK9 degrader-6 is a PROTAC targeting to CDK9 sepcifically. |
| M41432 | TP-1287 | TP-1287 is an orally active CDK9 inhibitor. |
| M41431 | CDK4-IN-2 | CDK4-IN-2 is a CDK4 inhibitor, with Ki and IC50 values of <10 nM. |
| M41430 | CDK2-IN-19 | CDK2-IN-19 is a selective and orally active CDK2 inhibitor (Ki: 0.18 nM). |
| M41429 | Albanol B | Albanol B is an arylbenzofuran derivative which can be isolated from mulberries. |
| M41428 | Crozbaciclib fumarate | Crozbaciclib fumarate is a CDK4/6 inhibitor with IC50s of 3 and 1 nM, respectively. |
| M41427 | Avotaciclib hydrochloride | Avotaciclib hydrochloride is the hydrochloride form of Avotaciclib, a CDK1 inhibitor. |
| M41426 | GW297361 | GW297361 is an oxindole CDK inhibitor that elicits a Pho85-selective response in cells. |
| M41425 | CDK7-IN-25 | CDK7-IN-25 (CY-16-1) is a CDK-7 inhibitor (IC50<1nM) that can be used in cancer research. |
| M41424 | CDK4/6-IN-17 | CDK4/6-IN-17 is an orally active CDK4/6 inhibitor with IC50 ranging of 10-100 nM in BE(2) cells. |
| M41423 | CLK1-IN-3 | CLK1-IN-3 is a potent and selective Clk1 inhibitor, with an IC50 of 5 nM and over 300-fold selectivity for Dyrk1A. |
| M41422 | LL-K8-22 | LL-K8-22 is a potent, selective and durable CDK8-cyclin C dual degrader, with DC50 values of 2.52 and 2.64 μM, respectively. |
| M41421 | ZNL-05-044 | ZNL-05-044 is a CDK11 inhibitor with an IC50s of 0.23 μM and 0.27 μM against CDK11A and CDK11B, respectively (NanoBRET assay). |
| M41420 | CAF-382 | CAF-382 is an analog of SNS-032 and a CDKL5 and pan-CDK inhibitor with a weak GSK3α/β affinity (>1.8 μM) and inhibitory activity. |
| M41419 | SHR5428 | SHR5428 is a potent, orally active, selective and noncovalent inhibitor of CDK7 with highly potent CDK7 enzymatic activity (IC50=2.3 nM). |
| M41418 | Leucettinib-92 | Leucettinib-92 is an inhibitor of DYRK/CLK kinase, The IC50s are 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM (CLK3), 124 nM (DYRK1A), 204 nM (DYRK1B), 0.16 μM (DYRK2), respectively. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
